Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.47 |
| ▸ | HTR3A | P46098 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5298446 | 0.82 | KCNH2 (0.62) | KCNH2CHRNA7HTR3A | |
| SCHEMBL5248865 | 0.80 | KCNH2 (0.59) | KCNH2CHRNA7HTR3A | |
| SCHEMBL4698821 | 0.80 | KCNH2 (0.67) | KCNH2CHRNA7HTR3A | |
| SCHEMBL5246025 | 0.79 | KCNH2 (0.55) | KCNH2CHRNA7HTR3A | |
| SCHEMBL373497 | 0.77 | CHRNA7 (0.65) | KCNH2CHRNA7HTR3A | |
| SCHEMBL5246818 | 0.76 | KCNH2 (0.65) | KCNH2CHRNA7HTR3A | |
| SCHEMBL5248418 | 0.75 | KCNH2 (0.67) | KCNH2CHRNA7HTR3A | |
| SCHEMBL6139396 | 0.75 | KCNH2 (0.73) | KCNH2CHRNA7HTR3A | |
| SCHEMBL5252885 | 0.74 | KCNH2 (0.62) | KCNH2CHRNA7HTR3A | |
| Bromide SCHEMBL5674269 | 0.74 | KCNH2 (0.72) | KCNH2CHRNA7HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006051413-A1 | AZABENOXAZOLES FOR THE TREATMENT OF CNS DISORDERS | PFIZER INC. (US) | 2006-05-18 | — | — | WO | claimed |
| EP-1831683-A1 | METHODS OF MODULATING THE ACTIVITIES OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR | Pfizer Products Inc. (US) | 2007-09-12 | — | — | EP | disclosed |
| US-20060142349-A1 | Methods of modulating the activities of alpha-7 nicotinic acetylcholine receptor | PFIZER INC | 2006-06-29 | — | — | US | disclosed |
| WO-2006067611-A1 | METHODS OF MODULATING THE ACTIVITIES OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR | PFIZER PRODUCTS INC. (US) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006051413-A1 | AZABENOXAZOLES FOR THE TREATMENT OF CNS DISORDERS | PFIZER INC. (US) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142349-A1 | Methods of modulating the activities of alpha-7 nicotinic acetylcholine receptor | CHRNA7, CHRNA5, CHRNA4 | KCNH2 451/4885CHRNA7 1/4885HTR3A 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.